Your email was addressed as a survey and the only link was the one I am responding to now.
To question #1; Did I receive the medication shipment as ordered?
The answer is yes, and I was impressed with the time in which it was delivered to my home; only 10 days!
To question #2; did the medication meet my expectations?
Again the answer is yes! I was also impressed with your website which explains everything about ordering outside the U.S., quality of the medication made at the India labs, number(s) to call if the shipment is held up in Customs, and the ease in placing the order.
- Dave
RTT NewsFDA Rejects Loxapine for ApprovalMedscapeMay 5, 2012 — The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) saying that the new drug application for loxapine inhalation powder (Adasuve, Alexza Pharmaceuticals, Inc) is not ready for approval in its current .
FDA again rejects Alexza's Adasuve, citing manufacturing deficiencies - The Pharma Letter
FDA again rejects Alexza's Adasuve, citing manufacturing deficienciesThe Pharma LetterLoxapine already is approved in a capsule form for long-term treatment of schizophrenia, but Alexza is seeking approval for an inhaled form that would be administered for acute agitation associated with schizophrenia or bipolar I disorder in adults.
Latest topics referred to NICE: May 2012 - dh.gov.uk
Latest topics referred to NICE: May 2012dh.
Benzinga's Microcap Movers for Friday May 4, 2012 - Benzinga
Benzinga's Microcap Movers for Friday May 4, 2012BenzingaAlexza Pharmaceuticals announced Thursday that it had received a Complete Response Letter from the US Food and Drug Administration regarding its New Drug Application for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.